Crescent Biopharma, Inc. (CBIO) Aandelenanalyse

Bedrijfsoverzicht

Crescent Biopharma, Inc. operates as a biotechnology firm dedicated to researching and developing novel cancer therapy candidates within the United States market. The company functions within the broader Healthcare sector and specifically within the Biotechnology industry, a field characterized by high capital requirements and significant regulatory scrutiny for product development. As of the latest reporting period, the entity maintains a market capitalization of $553.22M while employing a workforce of 44 individuals to advance its clinical pipeline. This combination of a substantial market valuation of $553.22M against an annual revenue of $10.84M indicates that the company is valued significantly above its current sales generation, a common trait for pre-revenue or early-stage biotechnology entities where future commercial potential outweighs historical financial performance.

Financiële gezondheid

Crescent Biopharma, Inc. reported revenue of $10.84M over the trailing twelve months, yet generated a net income of -$153,942,000, revealing a cost structure where expenses vastly exceed revenue generation. The company's EBITDA stands at -$152,548,000, further illustrating the heavy burn rate associated with advancing clinical trial candidates such as CR-001 and CR-002. Free cash flow for the period was -$153,697,632, indicating that the company is consuming cash reserves to fund operations and development rather than generating liquidity from core business activities. The financial statement displays a gross margin of 100.0%, which is typical for biotechnology companies in the research phase where cost of goods sold has not yet materialized at a significant level. Conversely, the operating margin is listed at -843.7% and the profit margin at 0.0%, figures that underscore the immense operational leverage and high fixed cost environment typical of drug discovery. The company holds cash totaling $213.19M against a debt level of $1.64M, resulting in a debt-to-equity ratio of 0.81 which suggests a balance sheet that is conservative in terms of leverage despite the negative earnings. The current ratio of 6.56 demonstrates robust short-term liquidity, as the firm possesses significantly more current assets than current liabilities to cover its immediate obligations. Return on Equity is calculated at -160.7% and Return on Assets at -69.1%, metrics that reveal that management is currently allocating capital to growth initiatives rather than generating shareholder returns through profit.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is -5.08, a metric that reflects the market's expectation of future earnings recovery or continued negative earnings in the near term. The price-to-book ratio stands at 3.03, indicating that the stock trades at a significant premium relative to its book value, a valuation multiple often seen in biotech stocks where intangible assets and pipeline potential drive the equity price. The price-to-sales ratio is 51.02, and the EV/EBITDA is -2.60, alternative valuation metrics that suggest the market is pricing the company based on its asset base and potential future cash flows rather than current profitability. Regarding trading range, the 52-week high is $29.00 and the 52-week low is $8.72, placing the current share price within a wide volatility band typical for small-cap biotechnology firms. The beta is listed as N/A, which implies that the stock's price volatility relative to the broader market is not captured by standard beta calculations, often due to the company's high correlation with specific clinical trial outcomes rather than general market movements.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company does not have sufficient historical data to calculate a growth rate or that the business is in a stage where growth is measured by pipeline milestones rather than financial percentage increases. Because the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available cash flow is retained within the company to fund research and development efforts. The absence of a dividend policy confirms that Crescent Biopharma, Inc. reinvests its limited earnings and cash reserves entirely into advancing its proprietary anti-PD-1/anti-VEGF bispecific antibody and other cancer therapy candidates. Consequently, the overall growth and income profile is characterized by zero current income distribution and a reliance on external capital or internal cash reserves to sustain operations until the next major clinical trial milestones are achieved.